Published in AIDS Weekly, April 7th, 2003
"amfAR pursues a research strategy that can be described as entrepreneurial," said Jerome J. Radwin, amfAR's CEO. "Much of this funding supports the study of viral reservoirs, where HIV may lie dormant despite years of antiretroviral therapy. These grantees and fellows will help describe viral latency, which may be the major factor preventing the eradication of HIV. Their work stands at the vanguard of current HIV research."
HIV can sequester itself in reservoirs in the body and in some cases remains...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.